Acquired by Staphyt SciReg was acquired by Staphyt in April 2025, indicating potential cross-sell opportunities into Staphyt’s broader regulatory and CRO services across Europe and Brazil, as well as access to integrated regulatory consulting and CRO capabilities.

Regulatory Focus Strong specialization in regulatory approvals with EPA and FDA, plus other international authorities, suggesting opportunities to offer expanded compliance, dossier preparation, and ongoing regulatory support to clients needing end-to-end regulatory solutions.

Industry Footprint Serving pesticide, plant growth promotion and protection, pharmaceutical, animal health, and chemical sectors positions SciReg to cross-sell to manufacturers across multiple high-regulation verticals facing approvals, renewals, and compliance updates.

Strategic Location Proximity to EPA and FDA headquarters in the Washington, DC metro area can be leveraged for faster regulatory intelligence services, client engagement, and potential collaboration with U.S. federal regulatory clients.

Mid-market Scale Revenue in the range of 1M–10M with 11–50 employees suggests a nimble team for targeted, high-value regulatory services, making it suitable for packaged offerings such as regulatory readiness assessments, expedited submissions, and ongoing compliance monitoring.